Literature DB >> 19300880

Use of CSF biomarkers in Alzheimer's disease clinical trials.

K Blennow1, H Zetterberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300880     DOI: 10.1007/s12603-009-0043-8

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  24 in total

Review 1.  CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.

Authors:  Kaj Blennow
Journal:  Expert Rev Mol Diagn       Date:  2005-09       Impact factor: 5.225

2.  Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Authors:  Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie
Journal:  Lancet Neurol       Date:  2008-07-30       Impact factor: 44.182

3.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Authors:  N Andreasen; L Minthon; P Davidsson; E Vanmechelen; H Vanderstichele; B Winblad; K Blennow
Journal:  Arch Neurol       Date:  2001-03

4.  Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

Authors:  I Skoog; P Davidsson; O Aevarsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

5.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

6.  First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.

Authors:  Sethu Sankaranarayanan; Marie A Holahan; Dennis Colussi; Ming-Chih Crouthamel; Viswanath Devanarayan; Joan Ellis; Amy Espeseth; Adam T Gates; Samuel L Graham; Allison R Gregro; Daria Hazuda; Jerome H Hochman; Katharine Holloway; Lixia Jin; Jason Kahana; Ming-tain Lai; Janet Lineberger; Georgia McGaughey; Keith P Moore; Philippe Nantermet; Beth Pietrak; Eric A Price; Hemaka Rajapakse; Shaun Stauffer; Melissa A Steinbeiser; Guy Seabrook; Harold G Selnick; Xiao-Ping Shi; Matthew G Stanton; John Swestock; Katherine Tugusheva; Keala X Tyler; Joseph P Vacca; Jacky Wong; Guoxin Wu; Min Xu; Jacquelynn J Cook; Adam J Simon
Journal:  J Pharmacol Exp Ther       Date:  2008-10-14       Impact factor: 4.030

Review 7.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

8.  Low frequency of post-lumbar puncture headache in demented patients.

Authors:  K Blennow; A Wallin; O Häger
Journal:  Acta Neurol Scand       Date:  1993-09       Impact factor: 3.209

Review 9.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

10.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

Authors:  Henrik Zetterberg; Mona Pedersen; Karin Lind; Maria Svensson; Sindre Rolstad; Carl Eckerström; Steinar Syversen; Ulla-Britt Mattsson; Christina Ysander; Niklas Mattsson; Arto Nordlund; Hugo Vanderstichele; Eugeen Vanmechelen; Michael Jonsson; Ake Edman; Kaj Blennow; Anders Wallin
Journal:  J Alzheimers Dis       Date:  2007-11       Impact factor: 4.472

View more
  8 in total

Review 1.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

2.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

4.  Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michelle M Mielke; H Randall Griffith; Abhay R Moghekar; Richard J O'Brien; Leslie M Shaw; John Q Trojanowski; Marilyn S Albert
Journal:  Arch Neurol       Date:  2011-01

Review 5.  Risk factors for the progression of mild cognitive impairment to dementia.

Authors:  Noll L Campbell; Fred Unverzagt; Michael A LaMantia; Babar A Khan; Malaz A Boustani
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

6.  A quantum dot probe conjugated with aβ antibody for molecular imaging of Alzheimer's disease in a mouse model.

Authors:  Li Feng; Hong-Yu Long; Ren-Kai Liu; Dan-Ni Sun; Chao Liu; Li-Li Long; Yi Li; Si Chen; Bo Xiao
Journal:  Cell Mol Neurobiol       Date:  2013-05-22       Impact factor: 5.046

7.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 8.  Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.

Authors:  Dana Kim; Young Sam Kim; Dong Wun Shin; Chang Shin Park; Ju Hee Kang
Journal:  J Clin Neurol       Date:  2016-10       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.